Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
The idea that exercise and physicial fitness may be associated with a reduction in risk of disease progression in men with relatively low-risk prostate cancer is hardly new, but
Filed under: Living with Prostate Cancer, Management, Prevention, Uncategorized | Tagged: activity, exercise, low risk, preventiuon, progression | 5 Comments »
According to data just reported in The Lancet, some men with low-volume, low-risk prostate cancer may be able to delay progression of their disease if treated only with the 5α-reductase inhibitor dutasteride (Avodart®).
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: dutasteride, low risk, Prevention, progression | 5 Comments »
A new report in Lancet Oncology offers guidance on which patients with prostate cancer who are initially treated with radiotherapy and 6 months of neoadjuvant androgen deprivation therapy (ADT) are at relatively high and relatively low levels of risk for prostate cancer-specific mortality.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen deprivation, cancer-specific, marker, mortality, neoadjuvant, progression, PSA, radiation, surrogate | 2 Comments »
According to a media release issued on Thursday by IRIS International, the U.S. Food & Drug Administration (FDA) has approved the company’s NADiA® ProsVue™ test as a prognostic marker that can “aid in identifying” men at reduced risk for recurrence of prostate cancer in the first 8 years after a prostatectomy.
Filed under: Living with Prostate Cancer, Management, Uncategorized | Tagged: NADiA, prognosis, progression, ProsVue, radical prostatectomy | Leave a Comment »
“Manserin” is a novel peptide originally derived from a larger secretory protein called secretogranin II. A newly published paper suggests that expression of manserin in human prostate cancer tissues may correlate with risk for clinically significant and progressive forms of prostate cancer.
Filed under: Diagnosis, Management, Risk | Tagged: expression, Gleason, immunohistochemistry, manserin, progression, risk | Leave a Comment »
As a mentioned earlier this week, a new article by Moyad and Klotz has suggested that it may be possible to carry out a randomized clinical trial to evaluate the impact of statin therapy on the progression of early stage prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cholesterol, delay, progression, red yeast rice, RYR, statin | 2 Comments »
An article in the April issue of Clinical Medical Insights: Oncology suggests that a rapid post-treatment increase in the PSA levels of men treated for localized prostate cancer with high-intensity focused ultrasound (HIFU) may indicate later risk for biochemical recurrence.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: HIFU, high-intensity focused ultrasound, progression, PSA, rapid, rise, risk | 3 Comments »
The issue of whether changes in diet and the use of supplements affect risk for and progression of prostate cancer is regular fodder for media coverage. One of the major problems is that there has never been a large, well-controlled clinical trial that could provide definitive (“level 1″) evidence in support of the clinical benefit [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: diet, low risk, MEAL, progression, vegetable | Leave a Comment »
One of the most controversial issues in the management of prostate cancer is whether testosterone therapy can be given to men who have or are at risk for the recurrence of this type of cancer. Such use of testosterone therapy has been contraindicated for many years, but recent data has started to question this longstanding [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: deficiency, progression, risk, supplement, testosterone | 5 Comments »
Out of the 600+ presentations at the IMPaCT meeting in Orlando last week, your correspondent somehow managed to overlook an interesting poster that offers new evidence in support of the potential benefit of statin therapy in the prevention and management of prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Prevention, progression, statin, trial | 2 Comments »
The NADiA® ProsVue™ test is a highly sensitive investigational PSA immunoassay.
Filed under: Living with Prostate Cancer | Tagged: prognosis, progression, ProsVue, PSA | Leave a Comment »
It appears that regular use of commercially available pomegranate extract really does have a significant impact on PSA doubling time (PSADT) among men with a rising PSA but no indication of bone metastasis.
Filed under: Living with Prostate Cancer, Management | Tagged: doubling time, extract, pomegranate, progression, PSA, PSADT | Leave a Comment »
We will presumably be at least a little wiser about this issue when data from the REDEEM trial are presented at the Genitourinary Cancers Symposium in Orlando on Thursday; however, data from Canada already suggest that 5α-reductase inhibitors (5-ARIs) affect progression of low-risk forms of prostate cancer.
Filed under: Living with Prostate Cancer, Management | Tagged: 5-ARI, active surveillance, dutasteride, finasteride, outcome, progression | 5 Comments »
We really have no idea what the “best” way is to treat men with progressive disease after first-line radiation therapy.
Filed under: Uncategorized | Tagged: cryotherapy, outcome, progression, radiation, salvage | 3 Comments »
As usual, some of our friends in the media are over-hyping a recent publication about the possible effects of a protein called FUS/TLS in the progression of prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: expression, FUS, FUS/TLS, progression, protein | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site